Palisade Bio Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, has announced an agreement with several accredited investors to exercise existing warrants to purchase up to 4,318,905 shares of common stock. These warrants have been exercised at a reduced price of $0.9047 per share, resulting in expected gross proceeds of approximately $3.9 million. The proceeds will be used for working capital and general corporate purposes. In exchange for the immediate exercise of these warrants, investors will receive new unregistered warrants, allowing them to purchase an additional 8,637,810 shares of common stock at the same exercise price, with a term of five years. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for this transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.